课题基金 / 基金详情

Pitt RBL

Pitt RBL
皮特·RBL
批准号:
10793942
负责人:
William Paul Duprex
金额:
$287.02万
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-08-18 至 2028-07-31

项目摘要

项目成果

William Paul Duprex的其他基金

相似基金

相关文献

中文摘要
翻译
总体来说 摘要: 大学疫苗研究中心(CVR)内的区域生物遏制实验室(RBL) 匹兹堡是感染生物学的生物安全3级(BSL-3)枢纽。RBL的使命有三个方面,即 致力于病原体的出现、进化和宿主间的传播,以研究肺炎的发病机制 新出现的传染病和加快临床前新干预措施和医疗的发展 预防大流行和生物防御的对策。我们的愿景是成为全球公认的、高度- 由感染生物学家组成的协作、创新和前瞻的团队,准备应对新出现的 国家和国际两级的生物威胁。整个工厂都在 选择试剂和毒素(DSAT)。它汇集了来自不同学科的感染生物学家和临床医生。 他们需要BSL-3和动物(A)BSL-3设施来进行广泛的病毒和细菌研究项目。 我们建议建立运营、实践和综合服务核心,并正式运营我们的 现有的结构。从RBL成立之时起,这些人就已经进化了,尽管他们已经 他们的目的,需要现代化,以确保他们将保持最新的和业务适合的目的。这个 核心业务部门将负责全面管理和预算成果预算。它将管理 每日、每周、每月和每年的BSL-3活动对于RBL的支助和服务部门至 功能。这将确保BSL-3实验室以最高标准运行和维护,并且它们 都是安全的。实践核心将支持RBL的所有基本职能,使科学 计划应得到严格管理,并确保可重现结果的总体数据完整性。它将提供 为新的RBL调查员及其团队提供必要的理论和实践培训 在BSL-3和ABSL-3生物遏制方面工作。它将提供生物安全和生物安保支持,并保证 工厂符合第一级选定代理注册实验室的所有现行合规性规定。集成的 服务核心将为内部用户和外部用户提供广泛的高质量BSL-3和ABSL-3服务 合作者。这些将由学术和服务主管严格监督,并与 一名外部RBL主任、其他BSL-3专家和一个内部科学咨询小组的协助。 匹兹堡对RBL的业务支持将确保我们准备好支持任何国家对 在发生另一场大流行或生物恐怖主义袭击时出现的一系列新出现的传染病。支持这一点 一群BSL-3科学家,他们可以在紧急情况下专注于研究新的病原体,肯定会带来红利。
英文摘要
OVERALL ABSTRACT: The Regional Biocontainment Laboratory (RBL) within the Center for Vaccine Research (CVR) at the University of Pittsburgh is the biosafety level-3 (BSL-3) hub for infection biology. The mission of the RBL is threefold, to work on pathogen emergence, evolution and host-to-host transmission, to study the pathogenesis of emerging infectious diseases and to accelerate pre-clinical development of novel interventions and medical countermeasures for pandemic preparedness and biodefense. Our vision is to be a globally recognized, highly- collaborative, creative and forward-facing team of infection biologists who are poised to respond to emerging biological threats both at the national and international level. The entire facility is registered with the Division of Select Agents and Toxins (DSAT). It brings together infection biologists and clinicians from a variety of disciplines who require BSL-3 and animal (A)BSL-3 facilities for their wide ranging viral and bacterial research programs. We propose to establish Operations, Practices and Integrated Services Cores and formally operationalize our existing structures. These have evolved from the time the RBL was established, and although they have served their purpose, require modernization to ensure they will remain current and operationally fit-for-purpose. The Operations Core will have overall management and budgetary responsibility for the RBL. It will administer the daily, weekly, monthly and yearly BSL-3 activities essential for the support and services arms of the RBL to function. This will ensure that the BSL-3 laboratories are run and maintained at the highest standards and they are safe and secure. The Practices Core will support all the basic functions of the RBL enabling scientific programs to be rigorously managed and ensuring overall data integrity for reproducible outcomes. It will provide the requisite theoretical and practical trainings to onboard new RBL Investigators and their teams who wish to work in BSL-3 and ABSL-3 biocontainment. It will provide biosafety and biosecurity support and guarantee the facility meets all current compliance regulations for Tier 1 select agent registered laboratories. The Integrated Services Core will deliver a wide range of high quality BSL-3 and ABSL-3 services for internal users and external collaborators. These will be rigorously overseen by Academic and Service Leads and reviewed annually with the assistance of an external RBL Director, other BSL-3 experts and an internal Scientific Advisory Group. Operational support for the RBL in Pittsburgh will ensure we are ready to support any national response to a range of emerging infectious diseases in the event of another pandemic or bioterrorism attack. Supporting this cohort of BSL-3 scientists, who can pivot to work on new pathogens in an emergency, is certain to pay dividends.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Operations Core
Integrated Services Core
Practices Core
Administrative Supplement for Upgrading the University of Pittsburgh Regional Biocontainment Laboratory within The Center for Vaccine Research
海外基金